PTCT
PTC Therapeutics IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Blend
$65.44-0.35%
Close Nov 6, 2026
- Market cap
- —
- 1 month
- +4.6%
- 3 months
- -12.3%
- 1 year
- -8.8%
- 52-week range
- $59.24$89.55
- Dividend
- No dividends on record
- Short interest
- 11.3% of float8.3M shares · settled Oct 15, 2026 · -9.4% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $1.16B
- Net income
- -$105.97M
- Free cash flow
- -$37.96M
- Book value
- —
- Total debt
- $636.03M
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- -9.2%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Read more
The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
- Website
- ptcbio.com
- Headquarters
- Warren, NJ, United States
- Employees
- 991
- Listed
- Jun 20, 2013
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 31, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Oct 29, 2026 | $357.8M | +69.6% | 93.4% | $25.1M | -$51.7M |
| Jun 2026filed Jul 30, 2026 | $360.5M | +101.5% | 94.5% | $149.0M | $83.5M |
| Mar 2026filed May 7, 2026 | $272.6M | -76.8% | 89.7% | $45.9M | -$2.8M |
| Dec 2025filed Feb 19, 2026 | $164.7M | -22.7% | 90.1% | -$81.6M | -$135.0M |
| Sep 2025filed Nov 4, 2025 | $211.0M | +7.2% | 45.1% | $3.0M | $15.9M |
| Jun 2025filed Aug 7, 2025 | $178.9M | -4.2% | 93.6% | -$35.0M | -$64.8M |
| Mar 2025filed May 6, 2025 | $1.2B | +459.7% | 98.9% | $970.2M | $866.6M |
| Dec 2024filed Feb 27, 2025 | $213.2M | -30.6% | 92.4% | -$162.4M | -$65.9M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 19, 2026 | $1.7B | +114.5% | 95.9% | $856.5M | $682.6M |
| Dec 2024filed Feb 27, 2025 | $806.8M | -14.0% | 92.9% | -$302.6M | -$363.3M |
| Dec 2023filed Feb 29, 2024 | $937.8M | +34.2% | 93.0% | -$439.5M | -$626.6M |
| Dec 2022filed Feb 21, 2023 | $698.8M | +29.7% | 93.6% | -$447.4M | -$559.0M |
| Dec 2021filed Feb 22, 2022 | $538.6M | +41.4% | 94.0% | -$374.4M | -$523.9M |
| Dec 2020filed Feb 25, 2021 | $380.8M | +24.0% | 95.0% | -$431.8M | -$438.2M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched PTCT. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
8,303,282 shares short
-865,051 shares (-9.4%) vs Sep 30, 2026
11.3% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
9,168,333 shares short
-570,586 shares (-5.9%) vs Sep 15, 2026
12.4% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
9,738,919 shares short
-89,235 shares (-0.9%) vs Aug 31, 2026
13.3% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
9,828,154 shares short
-392,892 shares (-3.8%) vs Aug 14, 2026
13.4% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
10,221,046 shares short
-345,203 shares (-3.3%) vs Jul 31, 2026
14% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
10,566,249 shares short
+732,269 shares (+7.4%) vs Jul 15, 2026
14.4% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind PTCT’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if PTCT is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
55 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 22 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
383 filers reported a long position in PTCT for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
52.4%
of the 100.5M shares 13-F filers reported
Moves vs Q1 2026
5 added2 trimmed
1 new · 1 unchanged · 1 not comparable
Net shares held
+1.8%
across the 8 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $1.1B · 14M shares | 14M | +7.8% |
| 2 | RTW INVESTMENTS, LP | $631.9M · 7.7M shares | 7.7M | Unchanged |
| 3 | Jupiter Topco LLC | $590.2M · 7.2M shares | 7.2M | — |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | $402M · 4.9M shares | 4.9M | +2.6% |
| 5 | STATE STREET CORP | $375.1M · 4.6M shares | 4.6M | +5.8% |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | $336.7M · 4.1M shares | 4.1M | +4.7% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $305M · 3.7M shares | 3.7M | +1.7% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $180.1M · 2.2M shares | 2.2M | -0.1% |
| 9 | TORONTO DOMINION BANK | $176.7M · 2.2M shares | 2.2M | -28.4% |
| 10 | WESTFIELD CAPITAL MANAGEMENT CO LP | $159.6M · 2M shares | 2M | New |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of PTCT file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| May 15, 2026 | JANUS HENDERSON GROUP PLC13G · passive · amended | 8.7% |
| May 15, 2026 | TORONTO DOMINION BANK13G · passive · amended | 3.7%under 5% |
| Apr 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.17% |
| Apr 29, 2026 | VANGUARD PORTFOLIO MANAGEMENT LLC13G · passive | 5.88% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for PTCT
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.